Stockhead on MSN1d
Dimerix banks initial $3.2m payment in Japanese pharma licensing deal for kidney drug
Special Report: Dimerix has received the initial payment of ¥300 million (A$3.2 million) in line with its recently announced ...
Stockhead on MSN3h
“Accelerate Action” to boost women’s leadership in Aussie healthcare sector
Australian healthcare sector leaders believe while progress has been made further work is needed to see more women in senior ...
HotCopper on MSN2d
Dimerix posts modest gain as first Japanese payment for DMX-200 lands
Dimerix Ltd (ASX:DXB) has confirmed its receipt of its first $3.2 million payment from Japan’s FUSO Pharmaceutical Industries ...
Stockhead on MSN2d
Health Check: Half-price sale as brokers ring the bell on Neuren shares
Some healthcare analysts believe Neuren Pharmaceuticals (ASX:NEU) shares should be worth more than double their current soft ...
kalkinemedia6d
Dimerix Reports Increased Net Loss for First Half of 2025
Highlights:,Financial Performance:,Dimerix recorded a widened net loss, reflecting an increase compared to the previous reporting period.,Share Movement:,The company's stock experienced a decline over ...
stockhead2d
Health Check: Half-price sale as brokers ring the bell on Neuren shares
Healthcare analysts say Neuren shares should be worth more than double what they are Biotech sector retreats in February, despite some record results Dimerix pockets $3.2 million payment from Japanese ...
The Australian Financial Review1d
Dimerix Limited
Dimerix pursues new product concepts and applies scientific knowledge to the discovery of products from early stage development through to commercialisation.
morningstar.com.au4d
Dimerix Ltd
Dimerix Ltd is a biopharmaceutical company developing new therapies in areas with unmet medical needs. The company is developing four product candidates: DMX-200 for FSGS; DMX-200 for diabetic kidney ...